Open in interactive viewer → charts, metric popovers & call review

Precipio Finally Puts a Number on It — and Half the Number Comes From the Boring Business

A $44M hematopathology microcap breaks a two-year silence on guidance with a $40M run-rate target, doubles a four-person sales force, and gets asked on its own call whether the math holds together.
PRPO · Earnings Call · 2026-11-10

From record-keeping to forecasting

On its face, Precipio's Q3 was an unremarkable quarter: total revenue of $7.3M against roughly $7M in Q2, adjusted EBITDA of about $400K, unchanged sequentially, operating cash flow of roughly $600K versus about $700K. Pathology contributed about $6.3M; the product division cleared $1M quarterly for the first time. Cash rose about $0.5M to above $3.5M, versus roughly $2.3M a year earlier. What made it a different call was the last third of the prepared remarks. For the first time in the twelve quarters of trajectory data we can see, CEO Ilan Danieli put a numeric stake in the ground: a product revenue run rate above $10M exiting 2027, from roughly $4M annualized today; pathology at roughly $30M annualized; combined, "exceeding $40 million." He was careful to frame it as an exit run rate rather than a revenue forecast — which is itself the tell. The prior quarter's keyword set was backward-looking, with "previous record" and "revenues increased" at the top. This quarter, aggressive goals and "ambitious objectives" appear, and the single biggest new concept in the company's entire keyword history lands this quarter: the recipe — used half a dozen times as the thing 2026 was spent discovering and 2027 is meant to scale.

for the first time, we were able to respond to the calls from the various investment banks and hedge funds looking to provide capital to Precipio with a polite but clear, no thank you. I can tell you, as the person responsible for raising money to keep the lights on for 15 years, that was a wonderful moment.

Ilan Danieli, CEO · 2026-11-10
The contrast with the prior call is stark. On 2026-08-17, the only analyst question in the Q&A was about a two-day trading burst: “can you guys offer any commentary at all on the unusually high trading last month when we traded about 800,000 shares in a 2-day period” — Adam Hutt, Analyst · 2026-08-17 — answered with a shrug and a nod to IR: “I think we're starting to see the fruits of some of the more IR activities that we're doing.” — Ilan Danieli, Executive · 2026-08-17 A quarter ago the story was tape mechanics. Now it is targets. That is a genuine regime change for this name.

The arithmetic hiding inside the $40 million

The headline obscures more than it reveals. Pathology at ~$6.3M a quarter is roughly $25M annualized, so the $30M exit target asks for about 19% growth — from a division one analyst pointed out has seen its growth rate slow over the last couple of quarters. Products, at ~$4M annualized, must roughly 2.5x. Add it up and the incremental ~$11M splits close to evenly: about $6M from products, about $5M from pathology. Nearly half the new dollars are supposed to come from the slower, less-discussed, cash-generating business — which is also, per Danieli, the segment that "continues to generate the majority of our operating cash flow." That makes the plan less of a moonshot and more of a barbell: growth from the new thing, funding from the old thing. Which brings the real question: four people. “I'm wondering why are you investing that much because I would have expected the current sales force with their experience under the belt and the distributors' relationships a little further seasoned than it was a year ago, that we could expect a certain amount of growth without any additional salespeople” — Unknown Analyst, Analyst · 2026-11-10 The CEO's answer is a timing argument, not a strategy argument: hires made early in 2026 only get productive mid-year, which means “it's unlikely that they'll even see revenue coming from the efforts until the beginning of 2027.” — Ilan Danieli, CEO · 2026-11-10 Hence doubling the sales reps to eight, on the logic that leads convert in 3 to 18 months and the fix for variance is simply more shots. The confidence line: “if we convert half of it, we're there.” — Ilan Danieli, CEO · 2026-11-10 Investors are asked to accept an unsized pipeline halving as the bridge.

Margins, cash, and the asterisk

The mix shift is the quiet bull case. Product gross margin sits in the high 40s to 50%, and the CEO expects that to step to the mid-60s on doubled volume and 70-75% eventually — “this will, at a higher scale, it would be a good 70%, 75% gross margin.” — Ilan Danieli, CEO · 2026-11-10 Consolidated gross margin tells the story of how far that shift has to travel: 20.9%, up 1.2 points year over year. Revenue is the other half of the recovery: about $15M on a trailing basis, +22% year over year. The balance sheet claim is real. Effective net cash of $3M, up 165% year over year — though still 82% below the $16M peak of 2021, so this independence is built on a small base. Here is the asterisk the call did not dwell on. The company pays a meaningful share of its wage bill in paper: stock-based compensation of $767K in the latest reported quarter, against roughly $600K of quarterly operating cash flow. That is roughly a quarter of gross profit, and it is why free cash flow less SBC remains negative. "Cash flow positive" is true and worth celebrating; it is also thin, and a doubling of headcount will test it. The capacity pitch is the most striking thing the new co-founder and COO said all call, and the most unverifiable:

we estimate that our existing operational infrastructure has the capacity to support approximately $100 million in annual revenue, roughly equally divided between pathology services and product manufacturing without requiring significant additional capital investment in our core facilities and equipment.

Ahmed Sabet, Management Team Member · 2026-11-10
That is operational infrastructure as a call option — already bought, already expensed, waiting for revenue.

What management stopped talking about

The loudest signal is absence. Reimbursement and regulatory risk owned this narrative for years: 2025Q2's top keywords were the FDA ruling on laboratory-developed tests, MolDx approval and NGS testing; as recently as last quarter, CMS fee schedule sat near the top of the list. This quarter, pathology is discussed purely as a cash engine and a run-rate target. No Medicare rate commentary, no LDT policy, no Change Healthcare-style disruption. Either the risk resolved or the company decided it no longer leads with it — and neither was said out loud. And one market-context caveat worth carrying into 2027. Guiding to an exit run rate is a specific genre of promise, and globally the phrase annualized revenue run rate sits attached to a basket of tickers that has de-rated roughly 30% over 90 days. The tape has grown tired of exit-rate math. Precipio is now selling exactly that, from a $44M market cap trading at 0.7x revenue, with the stock 5% lower over three months and 20% below its August high of $31.12. The plan is coherent in structure. But it depends on a pipeline the company will not size and a sales force it has not yet hired — and the market for run-rate stories is not what it was.